Zeiss to get new CEO

Article

Carl Zeiss's current CEO, Dr Michael Kaschke, has resigned his position on the company?s Management Board.

Carl Zeiss's current CEO, Dr Michael Kaschke, has resigned his position on the company's Management Board with effect from the end of 4 March 2010. Dr Ludwin Monz will be appointed as the company's new Chief Executive Officer to succeed Dr Kaschke intends to return as chairman to the Supervisory Board and will stand for election at the AGM on 4 March 2010.

Dr Ludwin Monz has been a member of the Management Board of Carl Zeiss Meditec AG since October 2007. He has been responsible for the largest strategic business unit Ophthalmic Systems. Previous to this, he directed the strategic business unit Microsurgery for six years.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Fluorescence lifetime imaging ophthalmoscopy (FLIO) reveals the brain's best-kept secrets
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Rayaz Malik, MBChB, PhD: The bold future of imaging lies in the anterior segment
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Modern monitoring strategies remove major barriers to retina care
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Tyson Brunstetter, OD, PhD, shares key takeaways from his keynote at the International SPECTRALIS Symposium
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
The cornea is the unsung hero of diagnosing neurodegeneration, says Rayaz Malik, MBChB, PhD
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Early intervention is crucial for long-term outcomes in paediatric gene therapy
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Robert Ang, MD, explains why a small-aperture IOL is "not a niche product"
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
ARVO 2025: Ocular and systemic mitochondrial diseases may be key to dementia diagnosis
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions
Related Content
A map or globe, with Europe emphasised under a magnifying glass. Concept image for European launch of Johnson and Johnson presbyopia-correcting Tecnis Odyssey IOL. Image credit: ©Pakawadee – stock.adobe.com

Johnson & Johnson launches presbyopia-correcting Tecnis Odyssey IOL in Europe

Martin David Harp
June 17th 2025
Article

The Tecnis Odyssey, launched in the US in October 2024, is now available in Europe, the Middle East and Canada

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Dinah Zur, MD. Concept image for retinal paediatric imaging and International SPECTRALIS Symposium in Heidelberg, Germany.

Differentiating physiology from pathology in the paediatric vitreous

Hattie Hayes;Dinah Zur, MD
June 14th 2025
Article

Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture

Scientists work in a lab, looking at microscopes while data is superimposed over the top of the photo. Concept image for clinical trial research and structural functional endpoints in ophthalmology. Image credit: ©metamorworks – stock.adobe.com

Imaging the ellipsoid zone line could change the global approach to clinical trials

Hattie Hayes;Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
June 13th 2025
Article

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Neeraj (Bean) Dhaun, MD, PhD. Image courtesy of Heidelberg Engineering.

Neeraj Dhaun, MD, PhD, says advances in OCT tech may positively impact patients with chronic kidney disease

Neeraj Dhaun, MD, PhD;Hattie Hayes
June 13th 2025
Article

Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium

Gereon Hüttmann, PhD, deputy head of the Institute of Biomedical Optics, University of Lübeck, Germany, presented on holographic optical coherence tomography (HOLO-OCT) at the International SPECTRALIS Symposium (ISS)

Gereon Hüttmann, PhD, introduces holographic OCT to a new audience

Hattie Hayes;Gereon Hüttmann, PhD
June 13th 2025
Article

The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium

© 2025 MJH Life Sciences

All rights reserved.